Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target

$41.51 +0.38 (+0.92%)

(As of 12/20/2024 05:16 PM ET)

Mirum Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 11 Analyst Ratings

Sell
0

Hold
0

Buy
11

Based on 11 Wall Street analysts who have issued ratings for Mirum Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 10 have given a buy rating, and 1 has given a strong buy rating for MIRM.

Consensus Price Target

$57.10
37.56% Upside

According to the 11 analysts' twelve-month price targets for Mirum Pharmaceuticals, the average price target is $57.10. The highest price target for MIRM is $68.00, while the lowest price target for MIRM is $39.00. The average price target represents a forecasted upside of 37.56% from the current price of $41.51.

Get the Latest News and Ratings for MIRM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Mirum Pharmaceuticals and its competitors.

MIRM Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	1 Strong Buy rating(s)	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	10 Buy rating(s)	10 Buy rating(s)	10 Buy rating(s)	7 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$57.10	$57.73	$56.27	$53.11
Forecasted Upside	37.56% Upside	32.77% Upside	44.44% Upside	77.04% Upside
Consensus Rating	Buy	Buy	Buy	Buy

Why I'm telling friends to avoid gold stocks (Ad)

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.

MIRM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MIRM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Mirum Pharmaceuticals Stock vs. The Competition

Type	Mirum Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	3.09	2.81	2.51
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	37.56% Upside	25,828.57% Upside	14.53% Upside
News Sentiment Rating	Positive News See Recent MIRM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/13/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00	+49.80%
11/13/2024	Citigroup 3 of 5 stars		Boost Target	Buy ➝ Buy	$65.00 ➝ $68.00	+55.64%
11/13/2024	Robert W. Baird 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$44.00 ➝ $50.00	+18.26%
10/17/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$47.00 ➝ $49.00	+23.64%
8/8/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$50.00 ➝ $60.00	+55.52%
8/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$62.00 ➝ $66.00	+69.40%
2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad) The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!]
6/18/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$31.00 ➝ $39.00	+23.30%
6/18/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Outperform ➝ Market Outperform	$66.00 ➝ $68.00	+106.06%
6/18/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$53.00 ➝ $57.00	+72.73%
6/17/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Skorney Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/17/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$48.00 ➝ $48.00	+56.66%
12/19/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Strong-Buy ➝ Strong-Buy	$78.00 ➝ $64.00	+117.80%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:54 PM ET.

MIRM Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Mirum Pharmaceuticals is $57.10, with a high forecast of $68.00 and a low forecast of $39.00.
: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mirum Pharmaceuticals in the last year. There are currently 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MIRM shares.
: According to analysts, Mirum Pharmaceuticals's stock has a predicted upside of 37.56% based on their 12-month stock forecasts.
: Mirum Pharmaceuticals has been rated by research analysts at Citigroup, HC Wainwright, Leerink Partners, and Robert W. Baird in the past 90 days.
: Analysts like Mirum Pharmaceuticals more than other "medical" companies. The consensus rating for Mirum Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MIRM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Why I'm telling friends to avoid gold stocks (Ad)

And if you’d like to get your hands on this, here you go, the complete breakdown.

This page (NASDAQ:MIRM) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mirum Pharmaceuticals (MIRM) Stock Forecast & Price Target